New psychoactive substances in Europe: Innovative legal responses. by unknown
Innovative legal responses 
June 2015
New psychoactive 
substances in Europe
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal 
Tel. +351 211210200 
info@emcdda.europa.eu I www.emcdda.europa.eu 
twitter.com/emcdda I facebook.com/emcdda
I Legal notice
This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by 
copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data 
contained in this document. The contents of this publication do not necessarily reflect the official opinions of the 
EMCDDA’s partners, any EU Member State or any agency or institution of the European Union.
Europe Direct is a service to help you find answers to your questions about the European Union.
Freephone number (*): 00 800 6 7 8 9 10 11
(*) The information given is free, as are most calls (though some operators, phone boxes or hotels may charge you).
More information on the European Union is available on the internet (http://europa.eu).
Luxembourg: Publications Office of the European Union, 2015
ISBN: 978-92-9168-823-4 
doi:10.2810/90544
© European Monitoring Centre for Drugs and Drug Addiction, 2015 
Reproduction is authorised provided the source is acknowledged. 
Photo credits: iStock, alamy.
Recommended citation: European Monitoring Centre for Drugs and Drug Addiction (2015), New psychoactive 
substances in Europe: Innovative legal responses, Publications Office of the European Union, Luxembourg.
Available online: www.emcdda.europa.eu/publications/2015/innovative-laws
 I Contents
4 I Introduction
4 I The challenge
4 I The legal responses
5 I Innovative legal responses
7 I Innovative laws: key elements
11 I Conclusion
11 I References
11 I Resources
Authors: Brendan Hughes and Michael Evans-Brown
4New psychoactive substances in Europe
I Introduction
The first report of this series of publications looked at 
developments in the market for new psychoactive 
substances from the perspective of the EU Early Warning 
System. The report examined the growth in the number, 
types and availability of these substances that has 
occurred recently, some of the factors driving this, and the 
increase in the harms caused by these substances as a 
result. In response to this growing problem, countries in 
Europe have developed a range of policy measures in order 
to reduce this availability, use and harm. One such 
measure is laws intended to regulate or prohibit various 
elements of the trade. The EMCDDA has already produced 
a number of publications and resources on these 
legislative developments, but this report takes a closer look 
at the more innovative legal responses that have been 
designed to address this challenge.
I The challenge
Drugs are controlled internationally under United Nations 
conventions in order to protect public health — they have 
certain risks, as assessed by the World Health 
Organisation. Countries signing the conventions are 
required to establish criminal penalties to deter and punish 
unauthorised trade in controlled substances. As it is a 
general principle that criminal law must be certain, the 
substances subject to such penalties must be clearly 
specified, which means listing them individually, or in some 
cases in tightly defined groups according to their chemical 
structure. On this basis, when a new psychoactive 
substance is identified, its risk to health should be 
assessed and then it could be included in the list of those 
controlled under the criminal law. Until about 10 years ago, 
psychoactive substances not listed for control within the 
conventions tended to emerge on the illicit drug market. 
They were limited to a handful of substances each year, 
which were typically passed off as controlled drugs such 
as MDMA (methylenedioxymethamphetamine), 
amphetamine or heroin. 
However, over the last decade, entrepreneurs have started 
selling substances not listed for control on the open 
market, reasoning that whatever is not expressly 
prohibited must be allowed for open sale. This manifested 
in the emergence of the ‘legal highs’ and ‘research 
chemicals’ markets, which took off in the mid-2000s with 
substances such as BZP (1-benzylpiperazine) and 
mephedrone, and products containing synthetic 
cannabinoids such as ‘Spice’. The combination of 
globalisation and innovation in communications 
technologies means that substances have been 
developed, produced, and marketed internationally at 
great speed, and sold openly in specialised ‘head shops’ 
in towns and cities as well as via the internet. Some of 
these substances are so new to the field that, at least 
initially, there is very limited evidence of public health risks 
— the risks being the primary justification for punitive 
control measures. Entrepreneurs have used the lists in the 
drug laws simply as exclusions from their potentially vast 
product range; yet very broad definitions that might 
control many substances can be so vague that a 
prosecutor has difficulty proving that distribution was a 
crime. Adding substances to the list obliges law 
enforcement to test for those substances, but technical 
and financial resources for the new tests are not always 
increased accordingly. Altogether, this rapid growth in the 
number and types of new psychoactive substances 
discovered and distributed in Europe, accompanied by the 
limited evidence of public health risks, has challenged the 
capacity, and sometimes the credibility, of national 
identification, risk assessment and control systems. And 
suppliers respond swiftly: by the time one substance is 
controlled, a replacement is already on the shelves. 
The latest update from the EU Early Warning System 
provides some insight into the size and scale of the 
European market (EMCDDA, 2015a). During 2014, 101 
new psychoactive substances were reported to the EU 
Early Warning System for the first time. This brings the 
total number of substances being monitored by the 
EMCDDA to more than 450 — close to double the 
number of substances controlled under the United 
Nations international drug control conventions — with 
more than half of these being reported in the last three 
years alone. Between 2008 and 2013, there was a 
seven-fold increase in the number of seizures reported by 
law enforcement across Europe, while in 2013 almost 
47 000 seizures weighing more than 3.1 tonnes were 
reported to the EU Early Warning System. The market for 
these substances has thus accelerated to a speed which 
the public authorities’ established response has 
struggled to match.
I The legal responses
Governments in Europe have responded to the 
challenges posed by the market in new psychoactive 
substance in different ways. Among these measures 
designed to reduce the availability and use of new 
psychoactive substances, three broad, sometimes 
overlapping, groups of legal responses can be identified. 
In the first group, existing laws which focused on 
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consumer or health protection, or medicines have been 
used. In the second group, drug laws have been modified, 
most commonly by introducing group definitions of 
substances under control. In the third group, innovative 
new laws have been developed to address these 
substances, in a few cases even defining a psychoactive 
substance by its effect rather than its chemical structure. 
Further information on the three groups of legal 
responses can be found in the online publication on legal 
approaches to controlling new psychoactive substances 
(EMCDDA, 2015b), but this short report focuses on the 
key aspects of the third group. 
I Innovative legal responses 
Three main aspects of the innovative legal responses can 
be identified: the criteria used to define the substance or 
the motivation for use; the listing mechanisms that reduce 
the time needed to control new substances; and the levels 
of punishment established. These are summarised below 
and followed by a country-by-country summary of the key 
elements of the law which includes: the wording used to 
legally define a new psychoactive substance; whether any 
criteria of harmfulness is included; the mechanisms used 
to assess and control a new psychoactive substance; 
whether a control measure is temporary or permanent; 
the agency responsible for enforcement; and the 
penalties possible.
I Criteria of psychoactivity, motive and harm
The definition of a substance as requiring control usually 
consists of two of the three following elements: a 
substance should be psychoactive; there should be a 
motive of abuse or intoxication; and there should be some 
possible harm or threat to health (see Table 1).
The Irish and Romanian laws set their definition of 
psychoactivity to a certain threshold, with the Irish 
requiring ‘significant’ mental disturbance or change (as in 
Portugal), and the Romanian requiring effects comparable 
to other substances controlled as drugs (as in Hungary and 
Portugal). Both also establish the capacity or likelihood of 
causing dependence as a criterion.
TABLE 1
Elements considered in innovative legal responses to new 
psychoactive substances
Defining 
psychoactive 
effects
Motive 
(abuse or 
intoxication)
Harm or 
threat to 
health
Austria + + +
Finland + +
Hungary + +
Ireland + Dependence
Latvia*
Poland + +
Portugal + +
Romania + Dependence
Slovakia + +
Sweden*
United Kingdom + +
Note: A mark indicates that the element is included in the definition.
*  In the legal responses of Latvia and Sweden there is no mention of those 
three elements in their laws, as the decision on qualification as a new 
psychoactive substance is taken by a separate entity (see the country 
summaries for more information).
I Listing of new psychoactive substances
In an analysis conducted in 2009, the EMCDDA 
considered the implications of the level of administrative 
decision required to list a substance as a drug, with a 
ministerial decree being approved much quicker than a 
change in a parliamentary law, but with a correspondingly 
lower level of scrutiny (Hughes and Blidaru, 2009). In the 
laws considered here, ministerial approval is required in 
Austria, Hungary, Portugal and Slovakia; approval of 
government is required in Finland, and Parliament in the 
United Kingdom (as the substance will be temporarily 
controlled as a drug); and in Latvia and Sweden, the 
decision will be taken by government agencies in the 
health sector (Table 2). The trade-off between the speed 
and supervision of control is important; in Finland, the law 
was only passed when the proposal for the decision to be 
taken by the Ministry of Social Affairs and Health was 
changed to the government, as it was felt that such a fast 
decision should be accorded due oversight. Three 
countries have a system in which no list of new 
psychoactive substances is established, but any 
substance meeting the criteria will be considered to 
qualify (Ireland, Poland, Romania) (1).
(1)  This approach was also attempted in the Portuguese autonomous region 
of Madeira in 2012, but it was struck down by the Portuguese 
constitutional court for vagueness.
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I Penalties for offences
The offences defined in the innovative laws relate mainly to 
the supply of new psychoactive substances (manufacture, 
import, sale or distribution), but some of the laws 
emphasise advertising the substances as a specific 
offence. The penalties for these offences range from 
simple confiscation and destruction of the product in 
Sweden, to a maximum of 14 years in prison in the United 
Kingdom. The high penalty available in the United Kingdom 
is due to the substance being temporarily considered as a 
controlled drug and thus attracting the same penalty as 
other drug supply offences. The most severe penalties 
available for the different legal measures are listed in 
Table 3. In Portugal and Slovakia, only a monetary fine is 
provided for, as the offence is considered administrative 
rather than criminal; this is also the case for manufacture 
or distribution in Poland. Non-criminal penalties may be 
chosen for reasons of proportionality against an uncertain 
harm, though Eurojust, the EU agency for judicial 
cooperation, has noted that such an approach may 
complicate judicial cooperation in transnational cases, 
when dual criminality may be required. Longer prison 
sentences are possible in Austria and Latvia in the case of 
serious health consequences, while Poland and Romania 
attach the most severe penalties to acts of advertising 
rather than distribution itself. Only two countries have 
established penalties for possession of new psychoactive 
substances for personal use, with Hungary criminalising 
possession of preparations that contain more than 
10 grams of a new psychoactive substance, and Latvia 
establishing possession for personal use as an 
administrative offence punishable by a warning or fine, 
with possible criminal liability if a further offence occurs 
within a year.
TABLE 2
Bodies deciding on inclusion of new psychoactive substances in list
Ministry Government or higher Other No list
Austria: Health Finland: Government
Latvia: Centre for Disease 
Prevention and Control
Ireland
Hungary: Human Capacities
United Kingdom: Home Office 
approved by Parliament
Sweden: Medical Products 
Agency, National Institute of 
Public Health
Poland
Portugal: Health Romania
Slovakia: Health
TABLE 3
Most severe penalties in legislation for supply of a new psychoactive substance
Imprisonment (years) Fine in EUR 
(if no imprisonment)
Confiscation  
(if no fine)Normal Aggravated
Austria 2 10
Finland 1 –
Hungary 3 or 5 5 or 8
Ireland 1 5
Latvia 2 5
Romania 2 or 3 5
UK 0.5 14
Poland
1  
(advertising)
–
250 000 
(manufacture or distribution)
Portugal – – 45 000
Slovakia – – 332 000
Sweden – – – Yes
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I Innovative laws: key elements
This section provides a country-by-country summary of the 
key elements of the innovative laws, which include: the 
definition of a new psychoactive substance, noting any 
criteria of psychoactivity, abuse or harmfulness; 
mechanisms used to assess and control a new 
psychoactive substance; whether a control measure is 
temporary or permanent; the agency responsible for 
enforcement; and the penalties possible.
The following information is provided in summary form for 
the purpose of contrasting the general approach being 
used in different EU countries. The reader should note that 
much of this information is based on translations of 
original legal texts that have not been certified.
Austria
Law: Psychoactive Substances Act 2012
Definition: Substances not subject to the UN conventions 
of 1961 and 1971 are listed if they have the potential for 
‘psychoactive effects’ (stimulating or depressing the 
central nervous system, resulting in effects such as 
hallucinations or disturbances in motor functions, 
perception, behaviour, mood) (s.1(2)), are likely to be used 
by certain sections of society and a threat to consumer 
health cannot be excluded (s.3). May include compound 
groups
Named exclusions: Substances placed on the market in 
accordance with drug, pharmacy or medicine import 
regulations as well as substances subject to the Narcotic 
Drugs Act (s.2)
Duration of control: Permanent 
Listed by: Ministry of Health Regulation (s.3)
Offences and penalties: Unauthorised production, import, 
export or supply is a crime if the supplier aims to benefit 
and intends that the product be used for its psychoactive 
effects. Punishable by up to two years imprisonment, or 
one to ten years if supply results in many serious injuries or 
a death (s.4). Seizure of any amount of a substance is 
possible even when there is no suspicion of supply (s.5). 
Customs may also confiscate imported/exported 
goods (s.7)
Enforcement: Law enforcement
Finland
Law: Narcotics Act (amended 2014), Criminal Code 
(amended 2014), Government decree 2014
Definition: ‘Psychoactive substances banned from the 
consumer market’ mean those substances used for 
intoxicating purposes that might be a danger to health and 
that have been decided to be made subject to control in 
accordance with the EU Council Decision or are positional 
isomers of such a substance and are neither medicines 
nor narcotic drugs (s.3). Evaluation by the Finnish 
Medicines Agency together with the National Institute for 
Welfare and Health, police and customs (s.3a)
Named exclusions: Medicines and narcotic drugs (s.3). 
There are provisions for exemptions when the substances 
may also have industrial or research uses (s.3b, s.23b)
Duration of control: Permanent
Listed by: Government Decree
Offences and penalties: Production, import, storage, 
keeping for sale or transfer is punishable by fine or up to 
one year’s imprisonment (Criminal Code, Ch.44 (Offences 
endangering health and safety), s.5a)
Enforcement: Law enforcement
Hungary
Law: Government Decree 66/2012, Decree 55/2014, Act 
XCV on Medicinal Products 2005 (amended 2015), and 
Criminal Code (amended 2014) 
Definition: A substance which appears on the market (or is 
formally notified to the EU Early Warning System) will 
undergo a formalised rapid assessment which must reach 
two conclusions. Firstly, the substance can affect the 
central nervous system, so it can change the mental state, 
behaviour or perception and therefore pose as serious a 
threat to public health as the substances listed in the 1971 
UN convention; and secondly, the substance has no 
therapeutic use (amended Act XCV s.15B). May include 
compound groups
Duration of control: Temporary, one year, renewable. Within 
one year of being placed on the ‘Schedule of NPS’, the 
drug must be risk-assessed, resulting in full drug control or 
transfer to the ‘Schedule of substances removed from the 
Schedule of NPS’. Absence of relevant information can 
extend the risk-assessment procedure by one year (or until 
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information becomes available with a risk assessment 
every two years). Compound groups will remain as long as 
any substance in the group fulfils the requirements 
(amended Act XCV 2005 s.15C)
Listed by: Ministry of Human Capacities Decree (Decree 
55/2014 includes schedule of new psychoactive 
substances) and Government Decree (Decree 66/2012 
includes a schedule of substances removed from the 
schedule of new psychoactive substances)
Offences and penalties: import, export, transport, 
manufacture — up to three years’ imprisonment (if 
aggravating circumstances, one to five years); supplying, 
placing on the market, offering or dealing — one to five years’ 
imprisonment (up to one year if a small amount; two to eight 
years with aggravating circumstances). Possession for 
personal use of more than a small amount (preparation 
contains more than 10 grams of new psychoactive 
substances) — up to three years (Criminal Code ss.184, 
184/A-D). Possession of a small amount is a misdemeanour 
which falls within the competence of the police
Enforcement: Law enforcement
Ireland
Law: Psychoactive Substances Act 2010
Definition: ‘Psychoactive substance’ means a substance, 
product, preparation, plant, fungus or natural organism 
which has, when consumed by a person, the capacity to: 
(a) produce stimulation or depression of the central 
nervous system of the person, resulting in hallucinations or 
a significant disturbance in, or significant change to, motor 
function, thinking, behaviour, perception, awareness or 
mood, or (b) cause a state of dependence, including 
physical or psychological addiction (s.1)
Named exclusions: Medicinal products, animal remedies, 
intoxicating liquor, tobacco products, food, controlled 
drugs, other substances specified by the minister (s.2)
Duration of control: Permanent
Listed by: No list
Offences and penalties: Selling, importing or exporting a 
psychoactive substance knowing or being reckless as to 
whether that substance is being acquired or supplied for 
human consumption (s.3). Publishing or displaying an 
advert to sell substances or to promote the consumption 
of substances for psychoactive effects with information 
about how or where to obtain them (s.5). On summary 
conviction, a fine not exceeding EUR 5 000 or 
imprisonment for a term not exceeding 12 months, or both; 
conviction on indictment, a fine or up to five years’ 
imprisonment, or both (s.20)
Enforcement: Law enforcement
Latvia
Law: Law on procedures for the legal trade of narcotic and 
psychotropic substances and medicinal products 
(amended 2013), Criminal Code (amended 2014) and 
Administrative Violations Code (amended 2014)
Definition: Substances that are not included in the lists of 
controlled drugs and for which the information has been 
obtained from the Early Warning System or from reports 
received from any of five named (forensic) authorities (Law 
on Procedures…, Article 4, part 2)
Duration of control: Temporary, one year
Listed by: Centre for Disease Prevention and Control
Offences and penalties: Unauthorised manufacture, 
acquisition, possession, transportation and transfer with the 
purpose of the distribution of new psychoactive substances 
or products; up to two years’ imprisonment, or up to five 
years if the offence has caused grave consequences 
(Criminal Code, Section 2481). Unauthorised acquisition, 
storage, transport or transfer of new psychoactive 
substances or products containing new psychoactive 
substances, without the intent to sell them; warning or fine 
of up to EUR 280. Crime if repeated within one year
Enforcement: Law enforcement
Poland
Law: Act amending the Act on Counteracting Drug 
Addiction and the Act on State Sanitary Inspection, 2010
Definition: ‘Substitute drug’, in the Act on Counteracting 
Drug Addiction (CDA), Art.4, is redefined by the amending 
law as a substance, product or plant used instead of, or for 
the same purposes as, a controlled drug, and whose 
manufacture or placing on the market is not regulated by 
separate provisions. The law makes no specific reference 
to whether the drug should first be considered as harmful. 
Previously, under the Act on State Sanitary Inspection 
(SSI), the inspectors were empowered to act against any 
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‘failure to meet hygiene and health requirements’. They 
now have the specific right to withdraw from trade a 
‘substitute drug’ for up to 18 months in order to assess its 
safety, if there is a justified suspicion that it might pose a 
threat to life or health. If the substance is judged to be 
potentially harmful, costs are borne by the supplier; if not, 
costs are paid by the state (amended Act on SSI, Art.27c)
Named exclusions: Substitute drugs are not governed by 
regulations on the general safety of products (amended 
Act on CDA, Art.4)
Duration of control: Temporary, up to 18 months (amended 
Act on SSI, Art.27c)
Listed by: No list
Offences and penalties: The penalty for manufacturing 
such drugs or introducing them into circulation is a fine by 
the state sanitary inspector of between PLN 20 000 and 
one million (about EUR 5 000 to 250 000) (amended Act 
on CDA, Art.52a). The penalty for advertising the 
psychoactive effects of a substance is up to one year’s 
imprisonment (amended Act on CDA, Art.68)
Enforcement: State sanitary inspector
Portugal
Law: Decree-law 54/2013
Definition: Psychoactive substances that pose a public 
health risk comparable to that posed by controlled drugs, 
from their effects on the central nervous system, with the 
ability to induce significant alterations in the level of motor 
function, as well as mental functions, namely reasoning, 
critical judgement and behaviour, often with states of 
delirium, hallucinations or extreme euphoria, with the 
ability to cause dependence and in certain cases, produce 
long-term or permanent damage to the health of 
consumers (Art.2). Any substance that is suspected to 
pose a grave risk to human health (Art.7)
Named exclusions: Permission may be given for supply 
when intended for industrial or pharmaceutical purposes 
(Art.4)
Duration of control: Permanent
Listed by: Ministry of Health (Art.3) 
Offences and penalties: Production, import, export, 
advertising, possession and distribution of these 
substances or their derivatives (Art.4): closure of the 
premises involved (Art.6), as well as administrative fines of 
up to EUR 45 000. Users are referred to a commission for 
the dissuasion of drug addiction (Art.10)
Enforcement: Portuguese Economy and Food Safety 
Authority
Romania
Law: Joint Ministerial Order establishing mixed teams to 
control new psychoactive substances (2011)
Definition: Order set up multidisciplinary teams of 
representatives from ministries (e.g. health, interior, 
agriculture) and health and consumer protection agencies, 
to target environments where ‘harmful unregulated 
psychoactive substances’ were being distributed or 
consumed. The group is tasked to enforce all existing laws 
in their respective fields to stem the distribution of these 
substances
Duration of control: Permanent
Listed by: No list
Offences and penalties: All relevant existing offences and 
penalties
Enforcement: Mixed teams
Romania
Law: Law 194/2011 laying down rules to counter 
operations with products likely to generate psychoactive 
effects, other than provided by current laws
Definition: Any product (‘substitute’, Art.2a) likely to 
provoke psychoactive effects similar to those caused by 
substances controlled under drug laws (Art.1). These 
effects are defined as stimulation or inhibition of the 
central nervous system provoking ‘changes in functions 
and mental processes and behaviour’, or ‘causing 
dependency’ (Art.2e). The law makes no specific reference 
to ‘harmful’ substances. It establishes a system of pre-
authorisation via the National Health Veterinary and Food 
Safety Authority evaluation commission. It takes about five 
months for a decision to be made (Arts.3-12)
Duration of control: Permanent
Listed by: No list
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Offences and penalties: (from February 2014) Distribution 
without a permit (particularly if consumption was likely): 
three months to two years’ imprisonment when the 
psychoactive effects are unknown but likely, and six 
months to three years’ imprisonment when the 
psychoactive effects are known (Art.16). Advertising the 
psychoactive effects: one month to one year’s 
imprisonment (Art.20). Claiming that the products are 
lawful: one to five years’ imprisonment (Art.17). No penalty 
for the possession of these substances for the purpose of 
use. Failure to ban access to website within 12 hours: fine 
of EUR 12 000–23 000 (Art.15.1)
Enforcement: Ministry of Health, National Authority for 
Consumer Protection, National Health Veterinary and Food 
Safety Authority, Ministry of Internal Affairs, Ministry for 
Information Society
Slovakia
Law: Law 40/2013, amending Act No 139/1998 Coll.; 
Ministry of Health Decree 298/2013
Definition: Substances for which there is reasonable 
suspicion of the existence of persistent or sporadic and 
deliberate abuse, which is accompanied by harmful 
physical or mental reactions (Art.16a(1) of amended Act 
139/1998)
Duration of control: Temporary. After three years a 
substance is either deleted from the list or is moved to the 
list of controlled substances following the normal 
legislative procedure (Art.16a)
Listed by: Ministry of Health (Art.16a(4))
Offences and penalties: Administrative breach of 
consumer law — selling, promoting or putting the life or 
health of consumers in danger — (Act No 128/2002 Coll. 
on the state control of internal market in consumer 
protection matters, and Act No 250/2007 Coll. on 
consumer protection): maximum fine EUR 332 000
Enforcement: Slovak Trade Inspection Authority
Sweden
Law: Act of destruction of certain substances of abuse 
hazardous to health (2011:111)
Definition: The substances covered by the act are goods or 
substances which: (1) the government has decided to list 
as narcotics or as goods injurious to health, or (2) are 
included in an international convention to which Sweden is 
adhering but where listing has not entered into effect, or 
(3) can be presumed to be injurious to health (Art.2)
Duration of control: Permanent
Listed by: Medical Products Agency and Swedish National 
Institute of Public Health
Offences and penalties: The only ‘penalty’ is confiscation 
of property. All matters are handled according to the 
Administrative Act (1986:223) and are not viewed as 
criminal offences. Certain protocols must be used and the 
decision can be appealed to court
Enforcement: Law enforcement
United Kingdom
Law: Police Reform and Social Responsibility Act 2011, 
amending Misuse of Drugs Act 1971
Definition: ‘Temporary class drug orders’ (TCDO) may be 
drawn up where a substance is misused or likely to be 
misused, and where that misuse is having, or is capable of 
having, harmful effects (amended Misuse of Drugs Act 
[MDA], s.2A(4)). To proceed with such an order, the Home 
Secretary must consult the Advisory Council on the Misuse 
of Drugs (ACMD). However, there is also an ‘urgency 
procedure’, to consult only the ACMD Chair, if the likelihood 
of misuse poses an urgent or significant threat to public 
safety or health (amended MDA, s.2B)
Duration of control: Temporary, one year (amended MDA, 
s.2A(6))
Listed by: Home Secretary with approval of Parliament 
(amended MDA, s.2A)
Offences and penalties: TCDOs apply only to supply-
related offences under the Misuse of Drugs Act (amended 
MDA, s.2B), and carry the same penalties as drug supply 
offences: 14 years’ imprisonment and an unlimited fine on 
indictment, or six months’ imprisonment and a fine of 
GBP 5 000 (about EUR 6 900) on summary conviction. 
Simple possession of a temporary class drug is not an 
offence. However, law enforcement officers with suspicion 
may search an individual and seize and dispose of 
anything they believe is a temporary class drug (amended 
MDA, s.23A) to prevent possible harm to the individual
Enforcement: Law enforcement
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I Conclusion
This brief report provides an overview of how different 
European countries are developing innovative legislative 
responses to a rapidly evolving market which challenges 
public health and drug policy. Countries are forced to act 
by the speed at which new psychoactive substances 
appear and their open sale, balancing the precautionary 
principle of rapid control against the credibility and 
enforceability of the criminal law which is not always 
backed by evidence of harm to public health. Lessons may 
be learned from observing the evolution of legislation in 
different countries and seeing how some responses may 
be later adapted according to subsequent findings. 
Continuous monitoring of the situation is necessary to 
ensure an effective public health response tailored to the 
needs and context of the particular country.
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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